New HIV Drug Passes Hurdle
Posted on: Friday, 29 September 2006, 15:00 CDT
The experimental HIV drug bevirimat passed another test -- showing no interaction with other commonly prescribed HIV drugs in a U.S. study.
Graham Allaway, president of Panacos Pharmaceuticals in Gaithersburg, Md., told United Press International that combined treatment of bevirimat and the protease inhibitor atazanavir (Reyataz, Bristol-Myers Squibb) did not increase levels of bilirubin, an indication of liver problems.
Atazanavir is known to cause bilirubin increases, but the combination of the two drugs in 24 healthy volunteers didn't increase that problem, Allaway said.
The research was presented at this week's Interscience Conference on Antimicrobial Agents and Chemotherapy, sponsored by the American Society for Microbiology.
Since it is likely that PA-457, which is now known as bevirimat, will be used with other drugs, we needed to test for interactions with likely treatment partners, said Allaway.
Bevirimat, now in phase 2b studies, is the first in the class of maturation inhibitors of HIV. It prevents the virus from performing the final act in the microbe's life cycle -- releasing virions into the blood stream.
Source: United Press International
Related Articles
- Schering-Plough HIV Drug Linked to Cancer in Mid-Stage Study
- China Starts to Test New Anti-HIV Drug
- Progenics' HIV Drug Put on Fast Track
- Bristol-Myers Grants Access to HIV Drugs
- Data Indicates Tanox HIV Drug Candidate Active In Vitro Against CCR5 and CXCR4 Viruses and Synergistic With Entry Inhibitor
- High levels of HIV drug cause mental problems
- Paying for HIV Drugs Endangers Treatment: MSF
- Monogram Biosciences Announces Medicaid Coverage for HIV Drug Resistance Testing in Texas
- FDA Says Hoffmann-La Roche Made Misleading Claims About HIV Drug
 |
 |
User Comments (0)
RSS Feeds